CTLT:NYE-Catalent Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 60.72

Change

+0.02 (+0.03)%

Market Cap

USD 3.10B

Volume

1.38M

Analyst Target

USD 102.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent Inc is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's segments include Oral Technologies, Medication Delivery Solutions and Development & Clinical Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
HLN Haleon plc

N/A

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
ELAN Elanco Animal Health

N/A

USD 7.59B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.67B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M
EBS Emergent Biosolutions Inc

N/A

N/A

ETFs Containing CTLT

ISCG iShares Morningstar Small.. 1,000.00 % 0.00 %

N/A

USD 0.57B
EVNT AltShares Event-Driven ET.. 2.99 % 0.00 %

N/A

USD 4.78M
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 2.77B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
MNA IQ Merger Arbitrage ETF 0.00 % 0.76 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
USLB 0.00 % 0.35 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 5.62B
TWOK 0.00 % 0.10 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

N/A

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.14% 76% C+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.14% 76% C+ 94% A
Trailing 12 Months  
Capital Gain 22.17% 53% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.17% 47% F 72% C
Trailing 5 Years  
Capital Gain 15.70% 63% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.70% 56% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 8.66% N/A N/A 66% D+
Dividend Return 8.66% N/A N/A 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.93% N/A N/A 17% F
Risk Adjusted Return 16.68% N/A N/A 38% F
Market Capitalization 3.10B 67% D+ 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.10 9% 3%
Price/Book Ratio 3.06 58% 29%
Price / Cash Flow Ratio 43.78 17% 5%
Price/Free Cash Flow Ratio -19.84 83% 94%
Management Effectiveness  
Return on Equity -25.39% 42% 15%
Return on Invested Capital 0.03% 25% 28%
Return on Assets -0.38% 25% 22%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector